Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 1, 2015, Pages 7-14

  Kinoshita, Shuji ^a   Kondo, Kazuoki ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Canagliflozin; DPP 4 inhibitor; Drug drug interaction; SGLT2 inhibitor; Teneligliptin

Indexed keywords

CANAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1; TENELIGLIPTIN; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG COMBINATION; GLUCOSIDE; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

AREA UNDER THE CURVE; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOTHERAPY; OPEN STUDY; PHARMACODYNAMICS; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CROSSOVER PROCEDURE; DRUG COMBINATION; DRUG INTERACTION; DRUG SCREENING; ETHNOLOGY; NORMAL HUMAN; PHYSIOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CANAGLIFLOZIN; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; DRUG EVALUATION; DRUG INTERACTIONS; GLUCOSIDES; HEALTHY VOLUNTEERS; HUMANS; MALE; PYRAZOLES; THIAZOLIDINES; THIOPHENES; YOUNG ADULT;

EID: 84918559571     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.982531     Document Type: Review

References (18)

1. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-31
2. Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodiumglucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013;9:763-75
3. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18
4. Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:810-18
5. Invokana-[Package insert]. Janssen Pharmaceuticals, Inc. Titusville, NJ; 2014;Available from: www.invokanahcp. com/prescribing-information.pdf [Accessed on 18August 2014]
6. Nakamaru Y, Hayashi Y, Ikegawa R, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica 2014;44:242-53.
7. Nakamaru Y, Hayashi Y, Sekine M, et al. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy Caucasian subjects in Germany. Clin Ther 2014;36:760-9 .
8. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61
9. Guidance for industry. Drug interaction studies-Study design, data analysis, implications for dosing, and labeling recommendations. Draft Guidance. 2012. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available from: http://www.fda.gov/downloads/drugs/guidancecompliance regulatoryinformation/guidances/ucm292362.pdf [Accessed on 1 October 2014]
10. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012;14:1040-6
11. Clar C, Gill JA, Court R. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2:5
12. Kaushal S, Singh H, Thangaraju P, et al. Canagliflozin: a novel SGLT2 inhibitor for type 2 diabetes mellitus. N Am J Med Sci 2014;6:107-13
13. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2013;6:187-95
14. Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 2014;15:749-66
15. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508
16. Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013;35:A33-42
17. Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther 2012;29:889-99
18. Kuhre RE, Frost CR, Svendsen B, Holst JJ. Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine. Diabetes 2014. [Epub ahead of print]